WIRWed 12-12-12

Week Three of What I’m Reading Wednesday! (#WIRWed, if you follow on twitter)

You may have noticed I didn’t post last week.  Well, I was elbow deep in ethics training, bloodborne pathogen training, and microscope training.  Sharing that information may have had this effect:

Not wanting to lose any of my new readers to sleep-induced workplace injuries, I decided to take a week off, but I’m back!

 

Uncanny how Jorge Cham can illustrate our lives as researchers so well (substituting thesis with proposal in the above cartoon, of course)!  As I was sharing about miRNA’s two weeks ago, I was formulating how these might be developed as an antiviral for acute infections and then I found this paper:

Great work Guo et al.!  Let me know if you want to do a collaboration!

 

Okay, so moving on, here are a couple more articles I’m reading this 12-cubed week of WIRWed:

 

I’m spending some time learning about ciliogenesis – or the development of ciliated cells.  Were you aware that every cell in our body has at least one cilia, used for motion, sensing, etc.  Cells that are multiciliated are terminally differentiated and are of importance to my research with influenza in a primary epithelial cell culture model.

 

This next article speaks to one of my first loves in virology – Hemorrhagic Fever viruses (HFV).  Okay, I’ll admit it, when I read The Hot Zone in high school, I was hooked and I forever wanted to wear a space suit and hunt for life saving monkey serum alongside Dustin Hoffman.  My dreams have matured (those suits get HOTTT inside!), but I still love HFV and studied one for my graduate thesis work.  The following article combines a new favorite topic of mine, viral immune evasion strategies.  The crystallized structure of the Marburg IFN inhibitory domain of VP35 with dsRNA is amazing!

 

That’s it for this week.  Let me know what you think of this week’s readings.  I’d love to get a conversation going!  Are you reading anything that you’d like to share?  Send a link!

, , , , , , , , , , , , , ,

No comments yet.

Leave a Reply